Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells

Dong Xiao, Candace S. Johnson, Donald L. Trump and Shivendra V. Singh
Dong Xiao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Candace S. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald L. Trump
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shivendra V. Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, time course response for effect of PEITC and PITC on proliferation of PC-3 cells as determined by trypan blue dye exclusion assay. B, dose response for effect of PEITC on PC-3 cell proliferation as determined by trypan blue dye exclusion assay. PC-3 cells were plated, allowed to attach overnight, and treated with DMSO (control) or desired concentration of the test compound (PITC or PEITC) for specified time intervals. Both floating and adherent cells were collected and used for counting of dead and live cells. Columns, mean; bars, SE (n = 3). *, P < 0.05, significantly different compared with DMSO-treated control (one-way ANOVA).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effect of PEITC and PITC on PC-3 cell cycle distribution. PC-3 cells were treated with DMSO (control) or 10 μm PEITC or PITC for 24 h. The cells were then stained with propidium iodide and analyzed using a Coulter Epics XL flow cytometer.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    A, ELISA-based quantitation of cytoplasmic histone-associated DNA fragments in PC-3 cells following a 24 h exposure to DMSO (control) or different concentrations of PEITC or PITC. Cytoplasmic histone-associated DNA fragments were quantified using Cell Death Detection ELISA kit from Roche Diagnostics according to the manufacturer's instructions. Columns, mean; bars, SE (n = 3). *, P < 0.05, significantly different compared with control (one-way ANOVA). B, Western blot analysis for the effect of PEITC and PITC on cleavage of PARP. Cells were treated with 10 μm PEITC or PITC for the indicated time intervals and harvested for preparation of cell lysates. The lysate proteins were subjected to Western blotting using antibodies that recognize cleaved PARP. Blots were stripped and reprobed with anti-actin antibodies to ensure equal protein loading. The experiment was repeated twice using independently prepared lysates, and the results were comparable.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    A, representative Western blots for the effects of PEITC and PITC on protein levels of cyclin B1, Cdk1, Cdc25B, Cdc25C, and phospho-Cdk1 (Tyr15). Blots were stripped and reprobed with anti-actin antibodies to correct for differences in protein loading. The experiment was repeated two or more times using independently prepared lysates to ensure reproducibility. B, effect of lactacystin, a specific inhibitor of proteasome, on PEITC-induced decline in Cdc25C and Cdk1 protein levels. Cells were pretreated with DMSO or 40 μm lactacystin for 2 h at 37°C and exposed to 10 μm PEITC for 24 h. Cell lysates were prepared and subjected to Western blotting using antibodies against Cdc25C or Cdk1. The experiment was repeated twice, and the results were comparable. C, effect of lactacystin on PEITC-induced cell cycle arrest. Cells were pretreated with DMSO or 40 μm lactacystin for 2 h at 37°C and exposed to 10 μm PEITC for 24 h. Both floating and attached cells were collected and processed for cell cycle distribution analysis following staining with propidium iodide. Columns, mean of three determinations; bars, SE. a, significantly different compared with DMSO-treated control; b, significantly different compared with PEITC alone group.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    A, representative Western blots for the effects of PEITC and PITC on levels of Bcl-2 family proteins. PC-3 cells were cultured in the presence of 10 μm PEITC or PITC for the indicated time intervals and processed for preparation of cell lysate and Western blotting. Blots were stripped and reprobed with antibodies against actin to correct for differences in protein loading. B, results of densitometric scanning of the immunoreactive bands corresponding to Bcl-2, Bcl-XL, and Bax for PEITC samples. Columns, mean; bars, SE (n = 3). *, P < 0.05, significantly different compared with control (one-way ANOVA).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    A, Western blot analysis for Bcl-2 protein expression using lysates from PC-3 cells stably transfected with empty vector (PC-3/neo) and Bcl-2 (PC-3/Bcl-2). B, effect of PEITC on proliferation of PC-3/neo and PC-3/Bcl-2 cells as determined by trypan blue dye exclusion assay. PC-3/neo or PC-3/Bcl-2 cells were exposed to DMSO or PEITC (5 or 10 μm) for 24 or 48 h. Both floating and attached cells were collected and used for trypan blue dye exclusion assay. Columns, mean; bars, SE (n = 3). The percentage of surviving cells did not differ significantly between PC-3/neo and PC-3/Bcl-2 cells at either concentration of PEITC at both time points. C, analysis of sub-G0-G1 cells in cultures of PC-3/neo and PC-3/Bcl-2 cells following a 24 h exposure to DMSO or PEITC (5 or 10 μm PEITC). Cells with sub-G0-G1 DNA content were quantified by flow cytometry following staining with propidium iodide. Columns, mean; bars, SE (n = 3). The fraction of sub-G0-G1 cells did not differ significantly between PC-3/neo and PC-3/Bcl-2 cells either at 5 or 10 μm PEITC.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Western blot analysis for (A) cleaved caspase-3 and (B) procaspase-8 and procaspase-9 using lysates from PC-3 cells exposed to 10 μm PEITC or PITC for different time intervals. Data are representative of at least two independent experiments with similar results. C, effect of general caspase inhibitor z-VADfmk, caspase-8 specific inhibitor z-IETDfmk, and caspase-9 specific inhibitor z-LEHDfmk on PEITC-induced apoptosis as determined by quantitation of cytoplasmic histone-associated DNA fragments. Columns, mean; bars, SE (n = 3). a, P < 0.05, significantly different compared with DMSO-treated control; b, P < 0.05, significantly different compared with PEITC alone group (ANOVA followed by Bonferroni's multiple comparison test).

Tables

  • Figures
  • Table 1.

    Effects of PEITC and PITC on PC-3 cell cycle distribution

    Treatment% Cells
    Sub-G0-G1G0-G1SG2-M
    Control (DMSO)4 ± 0.556 ± 115 ± 0.519 ± 0.5
    5 μm PEITC14 ± 3*42 ± 3*14 ± 0.531 ± 1*
    10 μm PEITC16 ± 1*34 ± 5*13 ± 136 ± 4*
    5 μm PITC4 ± 0.559 ± 114 ± 0.520 ± 1
    10 μm PITC4 ± 0.556 ± 0.515 ± 0.521 ± 0.5
    • Note: Cells were treated with DMSO (control) or different concentrations of PEITC or PITC for 24 h at 37°C. Both floating and attached cells were collected and processed for analysis of cell cycle distribution by flow cytometry following staining with propidium iodide. Data are means ± SE (n = 3).

    • ↵* ,P < 0.05, significantly different compared with control (one-way ANOVA).

PreviousNext
Back to top
Molecular Cancer Therapeutics: 3 (5)
May 2004
Volume 3, Issue 5
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells
Dong Xiao, Candace S. Johnson, Donald L. Trump and Shivendra V. Singh
Mol Cancer Ther May 1 2004 (3) (5) 567-576;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells
Dong Xiao, Candace S. Johnson, Donald L. Trump and Shivendra V. Singh
Mol Cancer Ther May 1 2004 (3) (5) 567-576;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement